Mars, maker of M&M's and Skittles, is turning to CRISPR gene editing to develop more resilient cacao plants, with the aim of ...

Vertex Pharmaceuticals recently reported a significant revenue jump to $2,965 million in Q2 2025. Despite this success, the ...

Fintel reports that on August 6, 2025, Wells Fargo upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an ...

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic ...

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.52 per share for the second quarter of 2025, surpassing the ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...